by Jordan Cleland
What you need to know: Finding the lowest effective dose of risperidone is important because it is often prescribed for long-term use to reduce irritability in children and adolescents with ASD. In this study, the low dose of risperidone (0.125mg/day) was ineffective at reducing irritability. The high dose (1.25mg/day) was found to be effective.
What is the research about?
Risperidone is an antipsychotic that has been approved for the treatment of irritability in children and adolescents with autism spectrum disorder (ASD). Finding the lowest effective dose is important because long-term use is common in young people with ASD. The lowest effective dose could minimize the potential for negative side effects, such as weight gain, dyslipidemia, hyperglycemia, and sedation. In this study, the authors hoped to find the lowest dose that was still effective at reducing irritability in young people with ASD. They also measured the side effects of the medication.
What did the researchers do?
Participants were aged 5-17 years old, with a diagnosis of autism. The researchers randomly assigned the participants to three groups: high dose, low dose, and placebo. The low dose group received 0.125 mg/day and the high dose group received 1.25 mg/day of risperidone, varying slightly depending on the weight of the participant (higher dose for higher weight). The drug’s effects were measured in several domains: irritability, social withdrawal, stereotypic behaviour, hyperactivity/noncompliance, and inappropriate speech.
What did the researchers find?
The high dose of risperidone proved effective at reducing irritability, and it also improved functional impairment, hyperactivity, and symptoms of obsessive-compulsive behaviour. Patients in the low dose group showed improved levels of stereotypic behaviour, but overall the lower dose was not as effective as the high dose in these domains. In both the high and low groups, increased appetite, sedation, drowsiness, and weight gain were the most commonly reported side effects. Most of these effects were reported more often in the high dose group than the low dose group. Overall, the placebo group showed very little changes. These results cannot be generalized to long-term risperidone use in this population, as the study was relatively short (6 weeks).
How can you use this research?
This study contributes a valuable piece of information about effective levels of dosing for patients. Physicians can use this research to prescribe the appropriate amount of risperidone for individuals with ASD and to share evidence-based information about potential side effects with patients.
About the Researchers
All of the authors reported a conflict of interest, as they are researchers at Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies.
Citation: Kent, J.M., Kushner, S., Ning, X., Karcher, K., Ness, S., Aman, M., Singh, J., & Hough, D. (2013). Risperidone dosing in children and adolescents with autistic disorder: A double-blind, placebo-controlled study. Journal of Autism and Developmental Disorders, 43, 1773-1783.
About the Chair
The Chair in Autism Spectrum Disorders Treatment and Care Research is dedicated to studying ways to improve the mental health and well-being of people with Autism Spectrum Disorders (ASD) and their families in Canada.
The Chair is funded by the Canadian Institutes of Health Research in partnership with Autism Speaks Canada, the Canadian Autism Spectrum Disorders Alliance, Health Canada, NeuroDevNet and the Sinneave Family Foundation. Additional support is provided by York University.
For more information, visit the Chair in Autism Spectrum Disorders Treatment and Care Research website at asdmentalhealth.ca